Braeburn Pharmaceuticals and Camurus (STO:CAMX) touted data today from a long-term Phase III study of its weekly and monthly buprenorphine depots in patients with moderate-to-severe opioid use disorder. The safety and efficacy study enrolled 228 patients and 71% of participants completed the 48-week treatment. The safety profile of CAM2038 was comparable to previous, shorter studies, […]
Drug-Device Combinations
Lyndra gets boost for drug delivery platform from U.S. allergy institute
Lyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the formulation and preclinical development of a once-weekly oral HIV treatment. The Watertown, Mass.-based company makes use of a sustained-release technology developed by Robert […]
Digital health start-up Amalgam Rx launches with insulin titration app
Digital health start-up Amalgam Rx launched today with the release of iSage Rx, which it touts as the 1st FDA 510(k)-cleared, prescription mobile app for insulin titration. The app allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to the needs of their patients with Type II diabetes. Patients record their blood glucose […]
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly served as CEO of Alcresta, where he led regulatory and financing strategies for the company’s 1st product approval and launch. He also worked as Incline Therapeutics’ […]
Medtronic wins FDA nod for Resolute Onyx drug-eluting stent
Medtronic (NYSE:MDT) said today that the FDA approved its Resolute Onyx drug-eluting stent. The Fridley, Minn.-based company touted its device as the 1st stent formed by a sinusoidal wave of cobalt alloy wire. The company incorporated a radiopaque inner core within the wire to boost visibility, according to Medtronic. The stent also features thin struts and a polymer […]
Wireless power source could enable ingestible drug delivery devices
Researchers from the Massachusetts Institute of Technology, Brigham and Women’s Hospital and the Charles Stark Draper Laboratory have developed the means to wirelessly power electronic devices that stay in the digestive tract indefinitely. The team suggests that these devices could be used as sensors in the GI tract or carry drugs to be delivered over […]
H&T Presspart, Hovione ink commercialization deal for inhaler tech
H&T Presspart said this week that it acquired the global rights to Hovione Technology‘s capsule-based dry powder inhaler. The company launched a next-gen version of the inhaler called PowdAir Plus at this year’s Respiratory Drug Delivery Europe. The PowdAir Plus device is made of plastic and its 4-component design lessens manufacturing, assembly and production costs, according […]
Artificial pancreas shows promise in pediatric study
A pilot study evaluating an artificial pancreas in children with Type I diabetes found that the device helped kids control their condition, according to researchers at the University of Virginia. The artificial pancreas was developed at the UVA Center for Diabetes Technology and features a smartphone powered by algorithms that wirelessly link to a glucose monitor […]
Boston Scientific looks to lead the drug-eluting PAD market
Angioplasty is not a new procedure – doctors have been widening obstructed arteries with balloons since the 1960s. But for years the medtech industry has been plagued with what Jeff Mirviss, president of Boston Scientific’s interventional peripheral biz, calls the procedure’s Achilles heel: Restenosis. For patients treated with bare balloons, half must have the procedure done again […]
United Therapeutics launches $250m share repurchase program
United Therapeutics (NSDQ:UTHR) said today that its board of directors approved the repurchase of up to $250 million of the biotech’s common stock. The share repurchase program is effective immediately and United said it will stay open until the end of 2017. The company can make purchases in the open market, accelerated share repurchases or in privately […]